Checkpoint Inhibitors in Metastatic EGFR-Mutated Non–Small Cell Lung Cancer—A Meta-Analysis

Journal of Thoracic Oncology

Volumn 12, Issue 2, 2017, Pages 403-407

  Lee, Chee Khoon ^a,b   Man, Johnathan ^b   Lord, Sally ^a,c   Links, Matthew ^b   Gebski, Val ^a   Mok, Tony ^d   Yang, James Chih Hsin ^e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c School of Medicine University of Norte Dame   (Australia)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

EGFR mutation; Immune checkpoint inhibitors; NSCLC; Predictive biomarker

Indexed keywords

ATEZOLIZUMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; NIVOLUMAB; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN;

ARTICLE; CANCER SURVIVAL; EGFR GENE; GENE MUTATION; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; CELL CYCLE CHECKPOINT; DRUG EFFECTS; GENETICS; IMMUNOTHERAPY; LUNG TUMOR; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MUTATION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 85015330057     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.10.007     Document Type: Article

References (15)

1. 1 Sequist, L.V., Waltman, B.A., Dias-Santagata, D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 3, 2011 75ra26–75ra26.
2. 2 Engelman, J.A., Jänne, P.A., Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer. Clin Cancer Res 14 (2008), 2895–2899.
3. 3 Engelman, J.A., Zejnullahu, K., Mitsudomi, T., et al. MET Amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007), 1039–1043.
4. 4 Takezawa, K., Pirazzoli, V., Arcila, M.E., et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2 (2012), 922–933.
5. 5 Jänne, P.A., Yang, J.C.-H., Kim, D.-W., et al. AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer. N Engl J Med 372 (2015), 1689–1699.
6. 6 Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
7. 7 Herbst, R.S., Baas, P., Kim, D.-W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2015), 1540–1550.
8. 8 Akbay, E.A., Koyama, S., Carretero, J., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 3 (2013), 1355–1363.
9. 9 Gainor, J.F., Shaw, A.T., Sequist, L.V., et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer (NSCLC): a retrospective analysis. Clin Cancer Res 22 (2016), 4585–4593.
10. 10 Smith, D.A., Vansteenkiste, J.F., Fehrenbacher, L., et al. Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR). [abstract] J Clin Oncol, 34(suppl), 2016, 9028.
11. 11 Fehrenbacher, L., Spira, A., Ballinger, M., et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
12. 12 Hui, R., Gandhi, L., Carcereny Costa, E., et al. Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro). [abstract] J Clin Oncol, 34(suppl), 2016, 9026.
13. 13 Rizvi, N.A., Hellmann, M.D., Snyder, A., et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 348 (2015), 125–128.
14. 14 Spigel, D.R., Schrock, A.B., Fabrizio, D., et al. Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. [abstract] J Clin Oncol, 34(suppl), 2016, 9017.
15. 15 Hellmann, M.D., Gettinger, S.N., Goldman, J.W., et al. CheckMate 012: safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. [abstract] J Clin Oncol, 34(suppl), 2016, 3001.